Obstructive Lung Disease

Is There an “Ideal” Cystic Fibrosis Candidate for Lung Transplantation?

By

Suzanne Bujara

Publish Date August 23, 2018

Lung transplantation can extend survival in patients with cystic fibrosis who have compromised lung function and increasing exacerbations.

Nontuberculous Mycobacterial Infection in Cystic Fibrosis: Treatment Recommendations

By

Brandon May

Publish Date January 13, 2020

A multidisciplinary team discussed exploring the management options for nontuberculous mycobacterial infection in patients with cystic fibrosis.

Differences in BAL Surveillance of Preschool Children With Cystic Fibrosis

By

Sheila Jacobs

Publish Date December 17, 2019

Significant differences have been observed from bronchoalveolar lavage surveillance conducted among preschool children with cystic fibrosis, according to their country of residence.

Diversity of Mycobacterium abscessus Subclones in Pediatric Cystic Fibrosis

By

Bradley van Paridon

Publish Date December 16, 2019

Sputum isolates of Mycobacterium abscessus may not reflect a patient’s full bacterial diversity.

Controlling Antibiotic Adverse Drug Reactions in Cystic Fibrosis

By

Britt Gambino

Publish Date November 8, 2019

The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.

Long-Term Azithromycin Reduced Need for IV Antibiotics in Cystic Fibrosis

By

Brandon May

Publish Date November 6, 2019

Treatment with azithromycin during a 5-year period was associated with reductions in the use of intravenous antibiotics and pulmonary exacerbations in children with cystic fibrosis.

Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis

Publish Date November 6, 2019

The percentage of FEV1 higher was at 4 weeks and through 24 weeks with treatment vs placebo.

FDA Approves Triple Combination Therapy for Cystic Fibrosis

By

Brian Park, PharmD

Publish Date October 23, 2019

The FDA has approved Trikafta for the treatment of patients aged 12 years and older with cystic fibrosis.

Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes

By

Heidi Moore

Publish Date October 19, 2019

Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.